This project aims to investigate the role of extracellular vesicles as potential diagnostic and predictive biomarker in thoracic cancers.
Malignant Mesothelioma (MM) is a fatal cancer of the mesothelium, caused primarily by exposure to asbestos. The disease has the poorest survival (6-25 month) and longest latency of any oncological condition (30-40 years) and is often diagnosed at an advanced stage with limited treatment options. Absence of diagnostic and predictive biomarkers, long latency period, and different pathological MM subtypes are the main factors contributing to the increased difficulty of its treatment. It has been reported that 2 Australian are diagnosed with MM every day, with a significant increase in death expected between 2020-2030. Extracellular vesicles (EV) have been established as a very promising source of biomarker discovery, with a great potential to assist with the diagnosis, prognosis and treatment response in different types of cancer in the clinical setting. This project will use cutting edge technologies and Artificial Intelligence to identify robust diagnostic and predictive EV-associated biomarkers for MM.
The opportunity ID for this research opportunity is 2926